This webinar will be hosted live and available on-demand
Tuesday, September 12, 2023
11:00 AM Eastern Time
Inflammatory bowel disease (IBD) is a major global health concern, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects. A major reason clinically successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.
In this webinar brought to you by Altis Biosystems, Bryan McQueen will describe the development of a new stem-cell derived intestinal epithelium model system for testing IBD therapeutic efficacy. Using this model system, researchers developed a suite of assays to probe epithelial barrier disruption, cytotoxicity, and pro-inflammatory cytokine release in response to the activation of prototypical IBD-associated cellular pathways.
Topics to be covered
- The benefits and limitations of dynamic stem-cell derived intestinal tissue models
- Developing RepliGut® Planar for use in discovering and evaluating anti-inflammatory therapeutics
- The importance of using rigorous quality metrics to ensure assay performance
Bryan McQueen, PhD